These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 38494551)
21. Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms. Chatain N; Koschmieder S; Jost E Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32806517 [TBL] [Abstract][Full Text] [Related]
22. [Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review]. Liu JX; Chen W; Xu KL Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):283-286. PubMed ID: 29397859 [TBL] [Abstract][Full Text] [Related]
23. Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation. Sakoda T; Kanamitsu Y; Mori Y; Sasaki K; Yonemitsu E; Nagae K; Yoshimoto G; Kamezaki K; Kato K; Takenaka K; Miyamoto T; Furue M; Iwasaki H; Akashi K Intern Med; 2017 Sep; 56(18):2481-2485. PubMed ID: 28824063 [TBL] [Abstract][Full Text] [Related]
24. Allogeneic hematopoietic stem-cell transplantation for myelofibrosis. Zhang L; Yang F; Feng S Ther Adv Hematol; 2020; 11():2040620720906002. PubMed ID: 32110286 [TBL] [Abstract][Full Text] [Related]
25. Transplantation algorithm for myelofibrosis in 2022 and beyond. Hernández-Boluda JC; Czerw T Best Pract Res Clin Haematol; 2022 Jun; 35(2):101369. PubMed ID: 36333063 [TBL] [Abstract][Full Text] [Related]
26. Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases. Song X; Qi J; Li X; Zhou M; He J; Chu T; Han Y Platelets; 2023 Dec; 34(1):2229905. PubMed ID: 37409458 [TBL] [Abstract][Full Text] [Related]
27. Ruxolitinib. Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628 [TBL] [Abstract][Full Text] [Related]
28. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Shahnaz Syed Abd Kadir S; Christopeit M; Wulf G; Wagner E; Bornhauser M; Schroeder T; Crysandt M; Mayer K; Jonas J; Stelljes M; Badbaran A; Ayuketang Ayuk F; Triviai I; Wolf D; Wolschke C; Kröger N Eur J Haematol; 2018 Sep; 101(3):305-317. PubMed ID: 29791053 [TBL] [Abstract][Full Text] [Related]
30. Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation. Khanlari M; Wang X; Loghavi S; Wang SA; Li S; Thakral B; Bueso-Ramos CE; Yin CC; Kanagal-Shamanna R; Khoury JD; Patel KP; Popat UR; Medeiros LJ; Konoplev S Ann Diagn Pathol; 2022 Feb; 56():151860. PubMed ID: 34823075 [TBL] [Abstract][Full Text] [Related]
31. Ruxolitinib: a new treatment option for myelofibrosis. Ganetsky A Pharmacotherapy; 2013 Jan; 33(1):84-92. PubMed ID: 23307549 [TBL] [Abstract][Full Text] [Related]
32. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Gill H Cells; 2022 Jul; 11(13):. PubMed ID: 35805191 [TBL] [Abstract][Full Text] [Related]
33. Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation. Zhu P; Lai X; Liu L; Shi J; Yu J; Zhao Y; Yang L; Yang T; Zheng W; Sun J; Wu W; Zhao Y; Cai Z; Huang H; Luo Y J Transl Med; 2024 Mar; 22(1):275. PubMed ID: 38481248 [TBL] [Abstract][Full Text] [Related]
34. Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation. Kröger N; Shahnaz Syed Abd Kadir S; Zabelina T; Badbaran A; Christopeit M; Ayuk F; Wolschke C Biol Blood Marrow Transplant; 2018 Oct; 24(10):2152-2156. PubMed ID: 29800615 [TBL] [Abstract][Full Text] [Related]
38. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia. Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P Front Immunol; 2021; 12():605766. PubMed ID: 34025637 [TBL] [Abstract][Full Text] [Related]
39. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Kröger N; Sbianchi G; Sirait T; Wolschke C; Beelen D; Passweg J; Robin M; Vrhovac R; Helbig G; Sockel K; Conneally E; Rubio MT; Beguin Y; Finke J; Bernasconi P; Morozova E; Clausen J; von dem Borne P; Schaap N; Schroyens W; Patriarca F; Di Renzo N; Yeğin ZA; Hayden P; McLornan D; Yakoub-Agha I Leukemia; 2021 Dec; 35(12):3551-3560. PubMed ID: 34023851 [TBL] [Abstract][Full Text] [Related]
40. Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A Retrospective Analysis from the Australasian Bone Marrow Transplant Recipient Registry. Lwin Y; Kennedy G; Gottlieb D; Kwan J; Ritchie D; Szer J; Milliken S; Browett P; Spencer A; Butler A; Bardy P; Greenwood M; Perera T; He S; McEwan A; Larsen S; Lai H; Purtill D; Tran S; Aarons D; Hamad N Biol Blood Marrow Transplant; 2020 Dec; 26(12):2252-2261. PubMed ID: 32861814 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]